Investigational therapy can be successfully undertaken using viral-and nonviralmediated ex vivo gene transfer. Indeed, recent clinical trials have established the potential for genetically modified T cells to improve and restore health. Recently, the Sleeping Beauty (SB) transposon/transposase system has been applied in clinical trials to stably insert a chimeric antigen receptor (CAR) to redirect T-cell specificity. We discuss the context in which the SB system can be harnessed for gene therapy and describe the human application of SB-modified CAR 1 T cells. We have focused on theoretical issues relating to insertional mutagenesis in the context of human genomes that are naturally subjected to remobilization of transposons and the experimental evidence over the last decade of employing SB transposons for defining genes that induce cancer. These findings are put into the context of the use of SB transposons in the treatment of human disease. 
Investigational therapy can be successfully undertaken using viral-and nonviralmediated ex vivo gene transfer. Indeed, recent clinical trials have established the potential for genetically modified T cells to improve and restore health. Recently, the Sleeping Beauty (SB) transposon/transposase system has been applied in clinical trials to stably insert a chimeric antigen receptor (CAR) to redirect T-cell specificity. We discuss the context in which the SB system can be harnessed for gene therapy and describe the human application of SB-modified CAR 1 T cells. We have focused on theoretical issues relating to insertional mutagenesis in the context of human genomes that are naturally subjected to remobilization of transposons and the experimental evidence over the last decade of employing SB transposons for defining genes that induce cancer. These findings are put into the context of the use of SB transposons in the treatment of human disease. G ene therapy-in many the phrase elicits a reaction of increased therapeutic possibilities and yet high risk to patients. The high potential is obvious. Natural and chimeric genes can produce products to restore homeostasis and provide clinical benefit. The question now is reducing the risk and broadening the appeal so that gene therapy can enter into the mainstream of clinical practice.
RETROVIRAL-ASSOCIATED ADVERSE EVENTS IN GENE THERAPY TRIALS
The high risk of virus-mediated transduction using recombinant retroviruses, first recognized in mice in 1983, 1 became clear in pilot clinical trials when 5 of 20 patients treated for X-linked severe combined immunodeficiency disease unfortunately developed leukemia 3 or more years after administration of the therapeutic retroviral vector. [2] [3] [4] Whereas 3 of the 5
were successfully treated for both immunodeficiency and leukemia, 2 have died. A linkage between the retrovirus carrying the therapeutic IL2gc
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gene and the leukemias was inferred based on a common region of integration upstream of a resident LMO2 oncogene in hematopoietic stem cells (HSCs). [5] [6] [7] [8] [9] [10] [11] Similarly, gamma-retroviruses, encoding the gp91
Phox gene for treatment of chronic granulomatous disease, 12, 13 have led to leukemia and 1 death, 14 demonstrating that the vectors were not synergistic with just 1 disease. These events in HSCs cemented the notion of the dangers of insertional mutagenesis and biological selection for the retrovirus-induced outgrowths of treated cells. [15] [16] [17] [18] In contrast, retroviral vectors carrying either the adenosine deaminase gene for treatment of adenosine deaminase-linked immunodeficiency [19] [20] [21] [22] [23] [24] or WASp for Wiskott-Aldrich Syndrome 25 have not been associated with similar adverse events. In the patients with chronic granulomatous disease, retroviral integrations regional to growth-related genes have been associated with enhanced proliferation. [26] [27] [28] [29] Currently, by using altered retroviruses and appropriate doses, adverse events have been avoided. [30] [31] [32] Thus, the linkage of vector integration and adverse mutagenesis is not unequivocal. In some cases, clonal expansion of treated cells was temporary and devoid of adverse effects. Indeed, limited expansion of transgenic cells had the potential of increasing the likelihood of successful gene therapy. Moreover, in contrast to early treatments of HSC, viral-mediated transduction of T cells for adoptive immunotherapy has not resulted in adverse outcomes. 33 Thus, cell-type does make a difference. Whereas HSC with elevated expression of growth-related genes can result in T-cell leukemia and/or lymphoma, comparable treatments of T-cells for adoptive immunotherapy has not resulted in undesirable clinical outcomes. [34] [35] [36] There may be differences between cell types for integration sites as well as the availability of endogenous genes for activation. Analyses of gamma retrovirusmodified hematopoietic stem cells show that integration sites were clustered often near genes involved in growth control and cell survival (eg, in 1 study 40% of insertions were clustered in only 0.36% of the genome). 37, 38 Retroviral parameters associated with integration effects and genotoxicity are under intense scrutiny. [39] [40] [41] [42] [43] [44] [45] [46] [47] These and other studies make it clear that only a small subset of all the integrations near proto-oncogenes actually cause transformation. [48] [49] [50] The deliberate use of insertional vectors to uncover oncogenes by inducing leukemia and solid tumors has exacerbated the concerns of insertional mutagenesis by the very same vectors when used for gene therapy. Retroviruses [51] [52] [53] as well as transposons [54] [55] [56] have long been used for this purpose, although to obtain a meaningful number of effects, cooperating mutations are required either by preselection of mice with identified gene knockout genotypes or by delivering multiple genetic hits to single genomes. [57] [58] [59] [60] Notably, as discussed below, screens with both types of vectors have revealed the involvement of multiple genetic alterations to induce cancer. One consequence of these studies has been the elucidation of the multiplicity of mechanisms by which insertions can induce mutations that lead to adverse events, as summarized in Fig 1. Thus, although patients with AIDS are at increased risk for some cancers because of their immune state, 61 it has been a surprise to many that lentiviral vectors based on the HIV-1 LTRs
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have not been found in preclinical and clinical studies to have associated adverse events stemming from either activation, inactivation, and/or alteration of splicing of endogenous genes. 62, 63 Although the absence of cancers and leukemias following integrations of lentiviruses (including those with AIDS) might be due to the ability of the lentiviral vectors to infect nondividing cells for therapeutic benefit 64 or their selection of a different set of genetic loci for integration 38, 39, [65] [66] [67] even though the integration of both is directed into outward-facing major grooves on nucleosomal DNA. 68 
NONVIRAL GENE THERAPY AND INSERTIONAL MUTAGENESIS
Nonviral gene therapy is an alternative to using viral vectors that presents an opportunity to avoid some of the issues such as preferential integration sites associated with most viruses. 69, 70 Our research has revolved around the use of the Sleeping Beauty (SB) transposon/transposase for gene therapy 71 with a recent focus on employing the SB system to introduce a chimeric antigen receptor (CAR) to redirect the specificity of human T cells. Transposons have 2 major advantages over viruses as gene therapy vectors. First, clinical grade manufacture and quality control, for use in many patients is easier, more reliable, and less expensive than employing clinical-grade virus. Second, unlike viral cargos that often are integrated either into or proximal to genes that can incur mutagenic risks, SB transposons have few known preferences for integration sites. 72 Nevertheless, as discussed later, insertional mutagenesis is always a concern.
Over the past 2 years, there have been significant findings in areas that pertain to genotoxicity and its impact on gene therapy. First, it is evident that endogenous transposons are far more active in human cells than was surmised until very recently. Two questions arise from these findings. (1) Do these elements induce similar genetic consequences as therapeutic transposons?
(2) Do cells have mechanisms to cope with insertional mutagenic agents? Second, the results from the 1000 Genomes Project 73 and ENCODE
Q4
project 74 have demonstrated that the interactions of genetic elements in our chromosomes are far more variable and complex than customarily thought. These findings are reviewed in the sections below.
In light of these recent discoveries, we have 3 objectives in this review that pertain to the use of SB transposons in the clinic. (1) Evaluate the relative impact of SB transposition in consideration of the apparent relatively high activity of endogenous genetic elements. (2) Evaluate the data from transposon-mediated induction of cancer in mouse studies in terms of risks to patients undergoing SB-based gene therapy. (3) Discuss approaches that are required for dealing with the identified risks of transposon-mediated adverse events in the clinic.
TRANSPOSONS AND NATURAL GENETIC VARIATION IN HUMAN CELLS
Approximately 45% of the human genome is composed of transposable elements 75, 76 and up to twothirds 77, 78 of chromosomes may be derived from transposons that have been adapted to support cell function. Transposons are divided into 2 classes. Class I transposons are retro-elements that spread by a copy-and-paste mechanism whereby the transposon is transcribed and the RNA transcript reversetranscribed for insertion elsewhere in the genome. Class II transposons, which include the SB system, are DNA sequences that can ''hop/jump'' from 1 site to the next via a cut-and-paste mechanism. The 2 classes of transposons have distinctive features that are important considerations in gene therapy.
Retrotransposable elements. Class I transposons comprise about 42% of the genome and are categorized into 4 subtypes. The first are long interspersed elements (LINEs) that are up to 6-8 kb in length; there are about 500-800,000 copies of these elements, of which about 100 are active and about 10 may be highly active (''hot'') as a result of encoding the necessary products for integration of their RNA polymerase II transcription product. 79 The second subtype of class I transposons comprises about 1.5 million short interspersed elements of about 100-300 bp that are transcribed by RNA polymerase III and litter the entire genome. The third category comprises a relatively undefined set of sequences that are several hundred bp in length and probably transcribed by RNA polymerase II. A fourth category comprises the nearly half-million retroviruslike, human endogenous retroviral sequences that appear to be remnants of retroviruses that invaded the genome over eons and since degraded; these account for about 8% of the human genome. Resurrection of a consensus human endogenous retroviral-K sequence Q5 indicated that these elements preferentially integrated into or proximal to transcriptional units. 80 Of a total set of nearly 3 million retrotransposable elements, only a subclass of LINEs, designated L1Hs, are active and responsible for insertional mutagenic events that result in genetic disease, 79, 81 including cancer.
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The activity of LINEs in cells and their potential for causing deleterious mutations in human genomes has been known for decades. [84] [85] [86] Nevertheless, the huge number of retro-elements, which have not been linked to disease-causing mutations, led to the inference that they were largely inactive and played roles mainly in genome evolution. [87] [88] [89] This notion was reconsidered when whole genome sequencing became available. 90, 91 Extensive L1 insertions were found in somatic neuronal cells. 92, 93 L1 mobilization appeared to occur in the absence of methyl-CpG-binding protein-2, a protein involved in global DNA methylation and human neurodevelopmental diseases. 94 Other studies found abundant new retro-element integrations, some of which were associated with cancer. 95, 96 A failure in epigenetic silencing may account for the rare cases of L1s introducing somatic genetic lesions, 97, 98 which are relaxed in germline cells. 99 L1 activity can trans-mobilize short interspersed element sequences as well. 100 Moreover, in the mouse genome endogenous retroviral elements can also spread, 101 web 4C=FPO   Fig 1. Genetic consequences of integration of therapeutic vectors into genomes. In this instance, a transposon vector is illustrated, but the considerations apply to any vector system. A therapeutic transposon can integrate into 4 general categories of chromatin. Heterochromatin will suppress expression of the transgene-no gain-of-function (GOF) or loss-of-function (LOF) will occur. The most desirable integration events will be into intergenic regions where the therapeutic gene (TG) will be expressed. Integration into or proximal to a transcriptional regulatory region can have several outcomes including GOF of the transgenic cassette, as well as either enhancement or loss of expression of the neighboring gene (gene X). As reviewed in the text, in some cases the transcriptional regulatory elements of the transgene can activate quiescent chromosomal genes. Integration of the transposon into a transcriptional unit may allow expression of the transgene but block expression of the host gene leading to a phenotypic loss of function because of blockage of the gene or alterations in splicing. Integration within some genes can also lead to a dominant gain-of-function (DGF) and/or production of a dominant-negative form (DNF) of the original gene X.
suggesting that there might be even more hopping elements in the human genome.
Assuming about 10 13 cells per human and just the 10 hot L1 retrotransposons, there would be around 10 14 potential mutagenic sequences in the average human; more than 10,000 per basepair of genomic sequence. Clearly, the controls over these elements are extraordinarily tight such that few actually remobilize. Nevertheless, given the immensity of this background of elements, there is a strong hint that the human genome has adapted to accommodate insertion of transposon sequences. The identity of these controls is at least in part epigenetic, and their induction remains to be clarified. Although retro-transposition and DNA transposition occur by different mechanisms (copy-paste compared with cut-and-paste), the phenotypic results will be similar when integration interrupts a genomic sequence that either encodes proteins or regulates their expression. As discussed in detail below, the SB transposase has little preference for integration into protein-encoding genes whereas retro-transposable elements appear to have a preference for integration into protein-coding genes. These controls over insertional damage by endogenous transposons will likely be relevant to transposons used for gene therapy.
DNA transposons. Class II transposons are DNA sequences that are excised from the genome for insertion elsewhere in the same, or different DNA molecule, by a cut-and-paste mechanism (Fig 2) . The transposon sequence that is excised is precise in that the termini of the transposed sequence are exact. However, when the donor DNA sequence is repaired, there is often a ''footprint'' that is left, which in the case of SB, appears to vary according to cell type, but often is a 5bp TAC(A/T)G insertion. 102 The approximate 300,000 class II transposons comprise about 3% of the human genome. Active class II transposons are defined by inverted terminal repeats that flank a transposase gene that commonly does not have a promoter and, thus, is dependent on integration proximal to an endogenous promoter. This feature keeps the transposon from remobilizing in most cases but does allow spread of the transposon under some circumstances when the transposase gene is activated. 103 In general, transposons and viruses are both natural pathways for introduction of new genetic material into cells. However, the general evolutionary strategy of many viruses is to infect and make many viral particles, regardless of consequences to the cell (organism), for further infection of other hosts. In contrast, transposons generally only occasionally insert into cellular genomes but are carried over evolutionary periods in all the offspring of the cell.
The Sleeping Beauty transposon/transposase system for gene therapy. We, and others, explored the potential of DNA transposons for use as vectors for transgene delivery 104 based on their capacity to accommodate genetic cargos of up to, and on occasions, more than 10 kbp 69, [105] [106] [107] (Fig 2) . No active class II transposon has been uncovered in the human genome, although many sequencing projects mask repetitive elements for convenience of analysis. Indeed, because active class II transposons are exceedingly rare but useful for gene transfer, the SB system (transposon plus cognate transposase) was resurrected from an approximate 14 million-year sleep from salmonid genomes. 104 As a result of its origin in fish (last common ancestor for fish and humans lived about 500 million years ago), the SB transposase does not recognize class II transposons in the human genome. Since its first use as gene therapy vector, 105 the transposase has been reengineered for increased activity, from SB10 104 through SB11 106 and other intermediates 108 to the extremely hyperactive SB100X. 109 Likewise, the inverted terminal repeat structure of original transposon, T, also has been re-engineered for greater activity to produce T2 and T3 106 as well as other versions. 107 For current clinical applications of the SB system, the active transposase gene is supplied in trans rather than being incorporated into the plasmid carrying the therapeutic transposon. As a result, the plasmid is smaller than it would be with the SB transposase expression cassette, which leads to more efficient delivery and transposition. 69, 106 However, a SB transposon can be on the same plasmid (cis) rather than on a different plasmid (trans) as the transposase expression cassette. This would reduce cost, as only 1 clinical-grade DNA plasmid would be needed, but this would be at the risk of decreased efficiency of gene transfer. This has ''real world'' implications because patients enrolled on clinical trials infusing genetically modified T cells have varying abilities to donate peripheral blood affecting the quality and quantity of T cells available for transposition. Thus, the ability to titrate the amount and ratio of 2 DNA plasmids coding for transposon and transposase facilitates the generation of patient-specific T cells.
The advent of the SB system demonstrated advantages of transposons as vectors-they are easy to use if they can be delivered into cells, they result in precise integration of a defined genetic sequence that is flanked exactly by the inverted repeats of the transposon, and each integration event is separate, 110 such that concatemers do not arise from transposition (note, concatemers of transposons are often introduced purposely into genomes by illegitimate recombination for insertional mutagenic studies described later in the review). A further advantage of the SB system, but not all other transposons, is that it requires only a TA Q6 sequence for integration, with very few preferences for integration unlike most integrating viruses. 111 There are about 200 million TA sites in the human genome, which is appealing for obtaining a wide distribution of integrated vectors. However, not all TA sites are apparently equal. SB transposons, unlike other transposons, appear to prefer ''flexible'' TA sites 112, 113 that can be screened in any genetic locus. 72 Nevertheless, of all of the integrating vectors currently under study, the SB system appears to have the least preference for integration either into or proximal to transcriptional units. 114 As a consequence, the SB transposon system has been developed as a leading nonviral vector for gene therapy (currently in clinical trials) that has the advantages of using naked DNA and chromosomal integration of the therapeutic expression cassette. The SB vector has been validated for ex vivo gene delivery to stem cells, including T-cells for the treatment of lymphoma, and SB transposons have been delivered to liver for treatment of various systemic diseases in mice, including hemophilia 105, 115, 116 and mucopolysaccharidoses types I and VII. 117 The possibility of remobilization of a transposon from residual transposase activity is a theoretical concern (Fig 3) . In most studies with a promoter that has a limited duration of expression such as the CMV Q7 early promoter, expression of SB transposase from an episomal plasmid is transient (eg, in the liver transcription of the SB transposase gene is reduced about 10,000 fold over the first few days following uptake by hepatocytes). 118 Human cells have developed self-defense mechanisms to prevent the continued transposases as derived protein degradation products can interfere with their enzymatic activity. 119 In addition, the transposase, since it is derived from fish, would be immunogenic a subject to immune mediated clearance. Nevertheless, the possibility of a few cells continuing to express transposase cannot be ruled out. When a SB transposon is re-mobilized, it will leave a ''footprint,'' an insertion or deletion that is variable in length, but often an addition of 5bp. 102 In an exon that encodes a polypeptide, this would result in a frameshift leading to an abnormal protein. Because (1) SB transposons do not have a pronounced preference for transcriptional units, (2) exons comprise no more than 2% of the human genome, and (3) the rate of excision of a transposon in a cell is less than 10 24 based on gene deliveries to liver 118 and in transgenic mice (section on transposonmediated induction of cancer, below), the chance of an adverse event is estimated to be less than 10 26 . It may be far lower-too rare to detect. Since few genes are haplo-insufficient, the probability of an adverse event occurring from mutation of a single allele will be significantly lower.
One reoccurring question is whether SB transposons might ''skip along a genome'' (serially inserting and excising) like a rock skipping across the surface of a pond before sinking into a final resting site. This is thought to be highly unlikely for 2 reasons. The first is evolutionary 120 ; such a process would damage genomes by leaving footprints and, thus, be counterproductive to minimal disturbance of the host genome. The second is based on the conserved nature of DDE Q8 transposases, including SB, 121 in which the flexible target sites for integration 72, 112 undergo bending to render strandtransfer irreversible by facilitating the snapping back of the integrated DNA following the concerted singlestrand invasion steps. 122 That is, upon integration, the 2 ends the transposon comprising the synaptimal complex would snap, like a mousetrap that has been sprung. In addition to explaining how transposases have evolved to avoid skipping, this mechanism explains why transposition reactions are so infrequent even when all the necessary components are in excess.
Alternative measures to prohibit sustained activity include supplying messenger RNA
Q9
(mRNA) transcribed in vitro as the source of transposase, 123 although the instability of mRNA and reliable delivery of sufficient quantities may introduce quality control issues if used for gene therapy. An alternative is to construct transposon-expression cassettes in which the promoter for the transposase gene is inside the transposon 124 ; with this configuration, expression of the transposase gene would cease, although there is the drawback the outward directed transposase-driving promoter then would be positioned to potentially activate transcription of nearby genes.
We have estimated potential problems of remobilization of SB transposons from data accrued from multiple studies conducted with mice. The multitude of remobilization experiments in mice using specialized SB transposons is discussed in detail below. In addition to the experimental approaches in mice, we can use evaluations of clinical quality-control criteria to estimate the possible extent of transposon hopping in transduced cells. Currently, SB mRNA can be detected by qRT-PCR Q10 in 100 ng but not in 20 ng of T-cell DNA; 1 mRNA/20ng of T-cell DNA corresponds to about 1 SB mRNA/2 3 10 10 cellular mRNA molecules. Since the average cell expresses about 10,000 mRNA species, 125 the detectable limit is equivalent to 1 SB mRNA in 2 3 10 6 T cells. In fibroblasts, transposition efficiencies are about 1% (unpublished compilations), which would suggest a maximal rate of 1 remobilization event in about 10 8 T cells if a single mRNA is adequate to provide the necessary level of transposase. Moreover, remobilization per se does not imply adverse consequences. The range in new sites into which a remobilized transposon carrying a therapeutic expression cassette integrates is the same as the range of original sites into which the transposon originally integrated. Because less than 2% of the genome comprises exons 74 and since integration of transposons causes little effect on endogenous genes, 126 the chances of remobilization into an exon would be about 1 event in 10 10 cells. Assuming that 10% of genes could contribute to a transformed phenotype, the chances of remobilization leading to an adverse event would be about 10
211 . This is a very low number that is consistent with the mouse studies described later in this review. The number is much lower than the background level of retro-transposition, described next. In the case of the current clinical trials, discussed below, up to 10 10 SB-modified T cells may be infused, which would suggest the odds of a remobilization event are up to 10%. However, the footprint would be inconsequential because the repaired integration site would have been mutated by the original insertion that would direct an alternative polypeptide that was partially encoded by the transposon's inverted terminal repeat. The new integration event would have the same probability of leading to an adverse consequence as any of the far more frequent original integration events.
Recent insights into chromosomal organization and gene expression in humans. Sequencing of genomes obtained from cancer cells has revealed the first direct information on the variation of mutation rates in chromosomes of somatic cells and the importance of chromatin organization and conformation. 127, 128 The ENCODE Q11 project, 74 which employed 147 different cell types found that far from being composed largely of ''junk'' DNA, about 80% of the human genome was involved in some sort of regulated event and that 95% of the genome was within 8 kbp of a proteinbinding site. Moreover, the landscape of transcription in human cells is diverse with about 40% of the genome being transcribed at levels that spanned six orders of magnitude for polyadenylated RNA and with the average gene having four splicing isoforms although there is always a dominant species that comprises 30% or more of the splicing alternatives for a given transcriptional unit. 129 Strikingly, a large proportion of the transcripts in the human genome appear to be initiated from repetitive elements, mainly retrotransposons. It is now clear that transcriptional activation is far more complex than thought heretofore. 130 Enhancer elements can work over long distances via chromosomal looping with only about 7% of the looping interactions being to the nearest gene. 131, 132 Clearly, physical proximity is not a simple predictor for gene activation by incoming transgenic expression cassettes. The selectivity of transcriptional regulatory proteins to interact with selective promoters may explain the pronounced lack of activation of endogenous genes that lead to cancer by enhancers in lentiviral vectors. These findings support earlier 539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592   593  594  595  596  597  598  599  600  601  602  603  604  605  606  607  608  609  610  611  612  613  614  615  616  617  618  619  620  621  622  623  624  625  626  627  628  629  630  631  632  633  634  635  636  637  638  639  640  641  642  643  644  645 findings that murine leukemia virus integration up to 100 kbp upstream of the c-myb locus could activate a linearly distal locus through chromosomal looping loci. 133 The insertion of transgenic DNA into chromosomes can alter epigenetic marks that affect gene expression, 98 and integrated retroviral cassettes are subject to epigenetic silencing through identified cellular proteins. 134 The advent of high throughput sequencing revealed a number of surprises. In sum, the interactions between regions of the genome that affect gene expression are complex and not based entirely on physical (linear) proximity. Cells have a bewildering level of variety in gene expression at both the transcriptional and RNA processing levels. Moreover, the genome appears to have the ability to assimilate transposable elements and even make use of them. All of these features strongly suggest that the genome is unexpectedly flexible in terms of events that would be expected to destabilize its panoply of functions. Recent findings from the 1000 Genomes Project and other whole genome sequencing projects support this assertion.
Genetic variation in the human population. Deep sequencing has found that insertions and deletions (indels), which are equivalent to insertions of transposons, are about 10-fold less frequent in the human genome than single nucleotide polymorphisms (22,000 vs 1800 per genome compared with reference) with up to 50% of the indels being novel in any given individual. 135, 136 More pertinent to the consequences of insertional mutagenesis, these studies have revealed that the average human genome has approximately 250 to 300 loss-of-function mutations, with 50 to 100 in genes related to human disease, 137, 138 and about 20 completely inactivated genes 139 as classified by the Human Gene Mutation Database [http://www.hgmd. org]. Studies of genome samples from individuals and families have recently shown that copy number variations, especially of L1 and Alu retro-elements, were found in somatic tissues from the same individual, with preferred integration into protein-coding genes, many of which regulate growth 82, 93, [140] [141] [142] but nearly none associated with disease. Thus, the human genome is not only highly variable, 143, 144 but it can sustain genetic hits from transposons without apparent genetic consequences. This conclusion is consistent with early studies of transposition in nematodes where it was found that despite a strong preference for integration into transcriptional units 145 many, if not most, integrations did not have a phenotypic effect. Detailed studies revealed that the transposons could be removed during pre-mRNA processing. 126 Genetic consequences of natural transposition and therapeutic transposition. One way of addressing insertional mutagenesis by SB transposon vectors is to compare nearly random insertion with natural variation and the germline mutation rate. The background mutational rate from the approximate 1800 indels/individual and the approximate 10 14 hot retrotransposable elements in a human may not be apparent due to epigenetic silencing or activation of immune responses that are able to detect aberrant cells. Thus, the number of potentially mutagenic elements is millions, if not billions, of fold greater than the number originating from gene therapy using SB transposons. Superficially, with the histories of gamma-retrovirus-and lentivirus-mediated gene therapies in mind, it would appear that the consequences of insertions of SB transposons carrying a therapeutic cassette with enhancers that are not designed to interact promiscuously with all promoters should be relatively small. The probabilities of adverse consequences can be further analyzed. As only approximately 1.2% of the genome encodes proteins, 74 about 98% of integrations are unlikely to affect protein sequences in any way other than their rates of expression, which can vary widely. The remaining 2% of integrations that might occur into exons must be viewed in terms of other conclusions from deep sequencing of human genomes. The average gene is multiply spliced giving isoforms that, for the most part, have undefined specific roles. Thus, only 1 of the isoforms of multiply spliced genes would be affected by an exonic integration, which may be the reason that background integration of retrotransposable elements does not cause as many adverse events as might be expected. As with retroviruses that can be epigenetically silenced, 146 SB transposons, epigenetic silencing and RNA interference are probable causes of either complete suppression or reduction in transgene expression. [147] [148] [149] [150] Although some transposase-like enzymes used for gene transfer (eg, the phiC31 recombinase) can cause chromosomal translocations, 151 the SB transposase is not associated with such activities when used for integration of a therapeutic expression cassette. 152 We note that the situation is different when an SB transposon is hopped out of a concatemer of transposons for integration elsewhere. As discussed in the following section, in this case chromosomal rearrangements have been observed close to the locus in which the concatemer resides. This situation will not be applicable in gene therapy settings where the chromosomes will not be pre-established to have multiple transposons in a single locus.
been used to induce cancer in transgenic mice via an insertional mutagenesis mechanism. 153, 154 This may indicate, upon initial consideration, that transposons are potentially dangerous from a genotoxicity perspective. However, more careful consideration of the differences between the experimental conditions generated in mice (described in the following sections) and those actually encountered by patients in a clinical setting reveals that cancer is an unlikely outcome as a side effect of therapeutic transposon delivery. First, in the mouse experiments, the transposon vectors are especially designed to induce alterations to endogenous genes. Second, the mouse experiments are done in a way that results in the mobilization of multiple copies of the transposon in every cell of a given tissue. Third, in the mouse experiments, the transposase enzyme is expressed continuously in all cells of a given tissue throughout the lifetime of the animal. Last, in most of the experiments described so far in mice, efficient cancer induction was only achieved if the mouse was genetically predisposed to cancer, often by including a tumor suppressor gene mutation in the background. These points suggested to us, even in consideration that humans have far more cells and longer life-spans than mice, that unless the above conditions are met, cancer would be an unlikely sequelae of one time transposon vector mobilization and transposition into human chromosomes. Indeed, our published and unpublished observations do demonstrate that cancer is not induced at any significant level unless a transposon is used that carries a strong promoter/ splice donor, is present in all cells in the body in multiple copies, and mobilized continuously for the lifetime of the animal. In addition, we have found that for most tissues, efficient cancer development requires a genetic background that confers predisposition to induction of cancer. Thus, given the limitations of using mice as a model system (fewer cells per organ and considerably shorter lives) in the setting of human gene therapy, we do not expect cancer as a likely side effect of use of transposon vectors.
General scheme for transposition-mediated mutagenesis in mice. We were led in our efforts to develop a flexible system for somatic insertional mutagenesis using transposons by a large body of literature, and our own work, on the induction of cancer in mice using murine leukemia viruses. Murine leukemia viruses can cause cancer by acting as an insertional mutagen, either inserting near and activating proto-oncogenes or inserting within and inactivating tumor suppressor genes. 155 The features of the integrated provirus that can cause these effects on endogenous genes, are the enhancer and promoter sequences within the long terminal repeats (LTR), the splice donor and acceptor within the body of the virus, or the polyadenylation site within the long terminal repeat. [156] [157] [158] The tumor DNAs can be used to isolate new candidate cancer genes, by using the integrated provirus as a molecular tag. Sites of the genome that are recurrently mutated by proviral insertion (ie, in multiple, independent tumors) are called common integration sites and have been shown by experience to harbor cancer genes.
We hypothesized that an SB transposon, designed to mimic the ability of a retroviral element to cause both gene loss-and gain-of-functions, could be used to ''tag'' cancer genes in solid tumors. The transposon, T2/Onc contains splice acceptors (SA)s followed by polyadenylation signals in both orientations (Fig 4) . Upon insertion into introns, these elements are designed to intercept upstream splice donors and elicit premature transcript truncation. Between the 2 SAs are sequences from the 5 0 LTR of the murine stem cell virus (MSCV), which contain strong promoter and enhancer elements that are methylation-resistant and active in stem cells. [159] [160] [161] Immediately downstream of the LTR is a splice donor for splicing of a transcript initiated from the LTR into a neighboring gene. In subsequent work, other promoter sequences replaced the MSCV LTR sequences and similarly effective transposons for myeloid leukemia 162 or carcinoma induction were created. 163 The original T2/Onc transposon and later derivatives are, thus, specialized to identify both tumor suppressors and oncogenes.
Transgenic lines harboring multi-copy (usually 25-200 copies) chromosomal concatemers of T2/Onc, or similar transposons, are used in these studies. Transposase can be supplied in a ubiquitous or tissue-specific manner. In both cases, cohorts of mice are aged for tumor development. Once tumors are harvested, the transposon insertions are PCR Q12 amplified and sequenced. Usually hundreds or thousands of insertions per tumor genomic DNA are identified. Regions of the genome and associated genes that are mutated by transposon insertion in multiple, independent tumors are sought using bioinformatic and statistical analyses. Clustering of insertions in certain regions, beyond what is expected by chance, indicates selection for the rare insertion events, among many neutral or negatively insertion events that can give the cell a selective growth or survival advantage. The accumulation of novel insertions throughout their genomes causes the eventual appearance of tumors in mice. The general use of the SB system for identification of cancer genes is illustrated in Fig 5. The insertion sites are analyzed by looking for T2/Onc insertions at reproducibly mutated genes. In this way, we can develop a cancer genetic fingerprint for various tumor types. When T2/Onc was combined with SB transposase in both wild-type and cancer-predisposed mice, there was either induction or acceleration of tumors and/or leukemia. 164, 165 In both cases, the SB-accelerated or initiated tumors were characterized by recurrent somatic, tumorspecific insertions that occurred at dozens of known and novel cancer-genes. The hyperactive SB11 transposase, 106 expressed from the nearly ubiquitous Rosa26 promoter in transgenic mice, has been used for most of these studies. When 2 different versions of T2/Onc were combined with the Rosa26-SB11 transgene in mice, the result was almost uniform development of T-cell malignancy, 165, 166 which in some mice co-occurred with glioma brain tumors. 166 Tissue-specific mutagenesis with SB has been used to develop informative models of various forms of human solid tumors. Tissue-specificity was achieved by using Cre-recombinase that could be activated in a tissuespecific manner to excise a loxP-flanked stop cassette that separated the SB11 complementary
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DNA from the Rosa26 promoter. Cancers and/or pre-neoplasias could be induced in mice in a variety of tissues, including the liver, gastrointestinal tract, brain (glioma and medulloblastoma), and the prostate. [167] [168] [169] For instance, analyses of over 16,000 transposon insertions identified 77 candidate Q14 colorectal cancer genes, 60 of which are mutated and/or dysregulated in human candidate colorectal cancer and thus are most likely to drive tumorigenesis. Moreover, analysis of the co-occurrence of transposon insertion sites within gastrointestinal Q15 tumors, using a model that assumes a Poisson distribution of insertions at TA dinucleotides, identified common co-occurring insertions that were detected more frequently than expected by chance (eg, Apc and Nsd1, 2 known tumor suppressors). 55 A screen for pancreatic cancer genes on a Kras G12D background has identified many candidate cancer genes and validated a novel epigenetically silenced tumor suppressor gene, USP9X. The experience of performing many of these studies in mice has shown that unless many conditions are met, tumor induction by transposon mobilization is not efficient. First, expression of the SB transposase by itself, neither has ever revealed any abnormalities in mice, nor an increase in cancer incidence, despite being expressed ubiquitously for the lifetime of the mice. This suggests that SB transposase does not cause significant chromosomal instability or mobilize endogenous mammalian Tc1/mariner-family transposons at a rate high enough to cause cancer. Similarly, mice carrying just the transposon vectors are normal with no increase in cancer when aged, compared with nontransgenic controls.
Our work also suggests that a strong promoter sequence within the transposon is required for efficient tumor induction. When the Rosa26-SB11 transgene was employed to cause body-wide, lifelong mobilization of a transposon vector called T2/GT3, which lacks a promoter but contains a SA and polyadenylation signal, there was no significant increase in cancer incidence compared with control mice. In stark contrast, as mentioned above, lifelong mobilization of T2/Onc-like transposons does cause an increase in cancer incidence attributable to insertional mutagenesis. This suggests that T2/GT3 lacks a critical element for efficient cancer induction, probably a promoter/splice donor sequence that allows efficient oncogene activation to occur. However, SB-catalyzed T2/GT3 mobilization in p53 1/2 mutant mice caused an apparent decrease in tumor latency, suggesting that a transposon without a promoter can accelerate tumor development in a cancer-prone genetic background (D.A. L., unpublished observations). Such studies highlight the influence that genetic background could have on genotoxicity by integrating vectors.
The importance of genetic background for oncogene discovery. As mentioned above, the efficient induction of T-cell malignancy 165 and myeloid leukemia 162 did not require tumor-predisposed genetic backgrounds. Moreover, a T2/Onc3, with a CAG promoter in place of the MSCV LTR efficiently induces a variety of solid tumor types at low frequencies without a predisposing background. 163 Tissue-specific mobilization of T2/ Onc is able to induce gastrointestinal track epithelial adenomas and adenocarcinomas in Villin-Cre cells in transgenic mice 167 and liver-specific mobilization of T2/Onc using albumin-Cre and Rosa26-loxP-flanked stop-SB11 mice can cause full-blown hepatocellular carcinoma in otherwise wild-type mice. 169 However, in most other tissue-specific mutagenesis experiments, mice do not develop tumors efficiently unless also carrying tumor-susceptibility mutations such as p53 R270H or Kras G12D . 170 Moreover, the expression cassette in the transposons contained only transcriptional control elements and RNA processing motifs that were designed to cause maximal chaos when inserted into or proximal to chromosomal genes. Such would not be the case when SB transposons are used for gene therapy. These studies have a bearing on the estimated risk for SB transposon vectors for causing cancer when used for human gene therapy. In the case of human gene therapy, the copy number of integrating vectors would be far fewer, ideally 1 or 2, rather than 25-200 per cell, as in mouse mutagenesis experiments. The vectors would not be designed for disruption of endogenous genes, by loss-or gain-of-function. Importantly, the period of transposon mobilization would be transient. Thus, the experience of mouse somatic mutagenesis experiments suggests that the development of malignancies as a side effect of therapeutic gene delivery to human cells using SB should be an unlikely event. The vector design, copy number, and duration of SB transposase expression are all fundamentally different than what occurs during the mouse somatic mutagenesis screens. Cancer induction in mice using SB mutagenesis was revealed to be an inefficient process requiring great efforts to maximize the number of transposon insertion mutations per cell and have many cells at risk for cancer development. Moreover, most screens have been done in strongly cancer-predisposed genetic backgrounds, a situation not likely to be often encountered in clinical settings. As discussed next, the SB system has been recently deployed for the genetic transformation of autologous and allogeneic T cells for investigational treatment of B-cell malignancies. In these clinical studies, a chimeric antigen receptor (CAR) is used to redirect the specificity of T cells to bind to the tumor-associated antigen (TAA) CD19. It is likely that about 5% of cancer patients treated with CAR-modified T cells carry some cancerpredisposing genetic alterations because it is thought that such a percentage of cases may have an inherited genetic component. Thus, it may be that potential mutations arising from insertions of SB transposons may be more likely to produce a secondary leukemia when used in T cells from patients with cancer.
TRANSPOSON-MEDIATED GENE THERAPY IN THE CLINIC
Concerns. Transposition was applied to practice in 2012 using the SB system to enforce expression of a second generation 171 CD19-specific CAR in T cells. The CAR redirects T-cell specificity for CD19 independent of major histocompatibility complex as antigen-recognition is mediated through the singlechain variable fragment Q16 domain of a CD19-specific monoclonal antibody and T-cell activation is initiated though chimeric endodomain. Adoptive transfer of CD19-specific T-cells in early clinical trials has shown therapeutic efficacy the based on expected loss of normal CD19
1 B cells and significant destruction of large numbers of malignant B cells. [172] [173] [174] [175] [176] Patients with large tumor burdens that are rendered lymphopenic through prior conditioning chemotherapy can experience the numeric expansion of infused CAR 1 T cells. If synchronous activation of the infused T cells occurs, then there can be supraphysiologic elevation of inflammatory cytokines and systemic toxicities. These adverse events may be temporarily delayed from the time of infusion as the numbers of in vivo CAR 1 T cells swells. However, the signs and symptoms can be managed through the administration of systemic corticosteroids as well as biologic agents that interrupt the inflammatory cascade. Infusion of CD19-specific CAR 1 T cells is currently warranted in patients at high risk from dying due to progressive B-cell malignancies. At present, most trials targeting CD19 infuse T cells that express CAR as a result of viral transduction. Indeed, hundreds of transductions and infusions of genetically modified T cells have been undertaken without apparent evidence of insertional mutagenesis. 177 Furthermore, targeting CD19 in patients with aggressive leukemias and lymphomas is justified as the ''on-target'' side effects because of lysis of normal B cells, and associated hypogammaglobulinemia is tolerated given the potential benefit of controlling or curing the underlying B-cell malignancy. Thus, the use of T cells as a cellular substrate and the expression of a CD19-specific CAR provide an appealing platform to assess the safety and feasibility of using the SB system for gene therapy.
The first-in-human trials using the SB system are currently underway at MD Anderson Cancer Center (INDs  14193, 14577, 14739, 15180) . Three of these pilot studies infuse patient-and donor-derived CD19-specific CAR 1 T cells after standard-of-care autologous and allogeneic hematopoietic stem-cell transplantation, including umbilical cord blood transplantation. A fourth trial infuses autologous CD19-specific CAR 1 T cells after lymphodepleting chemotherapy. These trials have passed institutional (CRC, IRB, IBC
Q17
) and federal (NIH-OBA and FDA
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) regulatory committees. The standard operating procedures and associated worksheets are in place to manufacture and release the genetically modified T cells in compliance with current good manufacturing practice for phase I/II trials. In preparation for these trials, data was accumulated regarding the ability of the SB system to enforce expression of a CAR. The CAR itself was modified to not only redirect T-cell specificity to CD19 but to employ an endodomain with 2 chimeric signaling motifs to achieve a fullycompetent T-cell activation event defined as CARmediated proliferation, cytokine production, and specific lysis. The introduction of the CAR was achieved by electro-transfer (using a commerciallyavailable Nucleofector device from Lonza) of supercoiled DNA coding for SB transposon, and transposition was achieved by co-electro-transfer of a supercoiled DNA plasmid coding for the hyperactive SB transposase, SB11. 178 T cells expressing stable integrants of CAR could be readily achieved through co-culture on designer artificial antigen-presenting cells (aAPC) in the presence of the soluble recombinant cytokines interleukin IL-2 and IL-21. The aAPC, derived from K562, were genetically modified to co-express CD19 as well as CD64 and the T-cell co-stimulatory molecules CD86, CD137L, and a membrane-bound mutein of IL-15. The recursive addition of these g-irradiated aAPC to the electroporated T cells results in the reproducible, rapid, and massive numeric expansion of CAR 1 T cells. The electroporation uses defined ratios of T cells, SB transposon, and SB transposase resulting in between 1 and 2 copy numbers of CAR per T-cell genome. 179 The propagation also uses defined ratios of T cells and aAPC to ensure efficient outgrowth of T cells with at least 80% expressing CAR emerging within a few weeks of electroporation. Long-term co-culture (28 days) with aAPC does not affect T-cell activity or function because the T cells can effectively lyse target tumor cells and produce cytokine in an antigendependent manner while maintaining a na€ ıve/memory phenotype. The CAR 1 T-cells can further effectively control B-cell tumor in an immunocompromised NSG Q19 -mouse model, thus, providing evidence for their persistence. Moreover, the T-cell telomere lengths are not shortened after co-culture. 180 Meeting the concerns. Toxicities correlated with infusion of genetically modified CAR 1 T cells can be divided into adverse events associated with (1) lymphodepletion of the recipient to improve engraftment, (2) triggering the CAR protein, and (3) those associated with integration of the CAR transgene. Patients that receive myelosuppressive or myeloablative chemotherapy to induce lymphopenia are at risk from opportunistic infections and toxicity from the administered drugs. Indeed, there has been 1 death attributed to administering cyclophosphamide in an elderly patient with bulky CLL that received CD19-specific CAR 1 T cells. 172 This adverse event appears to be an exception as lymphodepleting chemotherapy is associated with expected complications and can be managed by clinical teams' experiences in caring for medically fragile patients. There are toxicities arising from infusing CAR 1 T cells. There have been unexpected adverse events because of ''on target'' toxicities as the CAR recognizes tumor-associated antigen on normal cells. For example, reversible liver and biliary tract damage occurred in patients receiving CAR 1 T cells rendered specific for carbonic anhydrase IX. 181 However, 1 patient has died because of HER2/ neu-specific T cells recognizing this TAA, which was inadvertently expressed on normal lung parenchyma. 182 Such unforeseen toxicities may be ameliorated using an inter-patient T-cell doseescalation schema and pausing between cohorts of patients before dose-escalation to evaluate for emergence of delayed adverse events. Some expected on-target toxicities have occurred, and these may not lead to modification of the T-cell dose. This occurs when T cells target the B-lineage TAA, CD19. Recipients can lose their normal B-cell repertoire as the infused CAR 1 T cells do not distinguish between normal and malignant B cells. [173] [174] [175] [176] Loss of humoral immunity appears tolerable in patients at risk from dying from progressive B-cell malignancies.
However, these patients need monitoring of serum immunoglobulin levels and if hypogammaglobulinemia develops, then they benefit from intravenous immunoglobulin as they can succumb to viral infections. The coordinated activation of CAR by large amounts of TAA can lead to infusion-related toxicities. These can be delayed in time relative to the actual intravenous administration of T cells and are manifested as a ''cytokine storm.'' In severe cases, patients experience fever and degrading vital signs. These events can also be complicated by ''tumor lysis syndrome'' associated with (welcomed) destruction of large amounts of tumor cells. These adverse events are typically managed by administration of systemic corticosteroids. If there are continued symptoms then etanercept and tocilizumab may be given to control high levels of cytokines. Indeed, serial measurement of IFN-g and IL-6 in peripheral blood may serve as a biomarker for those patients at risk of developing a cytokine storm. The third type of risk associated with infusing CAR 1 T cells stems from insertional mutagenesis. Unlike gene transfer into hematopoietic stem cells, 17, 183, 184 there has not been a genotoxic event in genetically modified T cells. Indeed, hundreds of infusions have been delivered using mostly recombinant retrovirus to transduce T cells. 177 Nonviral gene transfer has been safely undertaken based on the electro-transfer of DNA into clinical-grade T cells. 185, 186 We have improved the integration efficiency of DNA plasmids using the SB system to integrate CD19-specific CAR into T cells for human application. Extensive in-process testing and release testing is undertaken prior to infusion of the SB-modified T cells. 178, 180 The in-process evaluations include undertaking PCR to exclude integration of SB11 transgene, measurement of the number of CAR integrants per T-cell genome, and assessing the diversity of the T-cell receptor to exclude the emergence of a clonal or oligoclonal population of genetically modified T cells that have superior proliferative advantage in culture and that might herald unwanted uncontrolled growth in vivo. To guard against this possibility we undertake a culturing assay to measure the potential for autonomous proliferation. This assay is in compliance with CLIA and is part of the release testing and thus recorded on the T-cell certificate of analysis. Other release tests include measurements of (1) sterility (bacteria, fungal, mycoplasma, endotoxin), (2) viability, (3) enumeration, (4) chain of custody (measurement of HLA class I), (5) identity (CD3 expression), (6) contamination (expression of CD19 and CD32 to exclude B cells and aAPC), and (7) expression of transgene. These SB-modified clinical-grade T cells are prepared in compliance with current good manufacturing practice for phase I/II trials at MD Anderson Cancer Center from peripheral and umbilical cord bloods.
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CONCLUSIONS
The barriers to widespread adoption and impact of gene therapy are chiefly in translating promising preclinical data to the human laboratory. Never before has there been so much promise to the therapeutic potential of genetically modifying the human genome. This golden era is tarnished by the contracting financial support that erodes the ability of investigators to evaluate the human application of gene therapy, which has been successfully practiced on the bench and in animals. The SB system provides a clear line of sight to test new gene therapy. The low cost of manufacturing clinicalgrade SB plasmids and availability of expertise to manufacture these expression vectors within the non-profit (eg, Production Assistance for Cellular Therapies under the auspices of the National Heart, Lung, and Blood Institute) or for-profit sectors contrasts with the expense, uncertainty, and lengthy timeline to manufacture recombinant clinical-grade virus. After passing institutional and federal regulatory reviews, the first patients have now successfully received T cells genetically modified with the SB system. 188, 189 This new approach to gene therapy employs a commercially available electroporation device and readily available APCs. This lays the groundwork for other groups to adopt the SB system for human application of cells other than T cells and transgenes other than CARs.
Future directions-Expanding the potential of transposonmediated gene therapy. Until a few years ago, many labs pursued the goal of identifying ''safe havens'' for integration of therapeutic vectors. 190, 191 Zinc finger nucleases (ZFNs) were first used for introducing double-strand breaks at specific sites in the genome to facilitate site-specific recombination of an expression cassette. [192] [193] [194] [195] [196] [197] The first attempts to combine the targeted integration ability of zinc fingers with SB transposons consisted of adding a zinc-finger DNAbinding domain to SB transposase, 198, 199 which resulted in diminished SB activity and marginal targeting. More recent approaches have employed either a targeted zinc-finger nuclease-mediated doublestrand DNA break, 200 the adeno-associated virus Rep protein, 201 or targeting ribosomal RNA genes. 202, 203 Both strategies report better outcomes. The advent of TAL-effector nucleases (TALENs) for directing double-strand DNA breaks with increased resolution and ease, and perhaps accompanied with lower rates of off-targeting, should facilitate insertions of therapeutic cassettes into selected sites in the genome. 204, 205 The electro-transfer of DNA plasmids coding for the SB system has been used to stably integrate a CAR into clinical-grade T-cells. The transposition event can be harnessed to introduce multiple transgenes by synchronous electro-transfer of SB transposons from multiple DNA plasmids. Using the DNA plasmids as ''building blocks'' allows investigators to generate populations of cells by combining sets of DNA plasmids expressing 1 or more transgenes while employing the same methodology and importantly the same standard operating procedures in a GMP facility. The SB system can also be combined with genetic editing tools such as designer ZFNs and TALENs. 206 Although we have calculated extremely low odds that integrated SB transposons will cause an adverse effect, either by initial integration or by potential remobilization that leaves a frame-shift footprint in a proteinencoding gene, the chance is not zero. In consideration of this possibility, the addition of a suicide gene, iCasp9, has been engineered into a piggyBac transposon. In this system, administration of a small chemical inducer, AP20187, will direct dimerization of mutant Caspase-9 polypeptides leading to cell death. 207 This approach is available for other transposons.
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